Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus whole-brain radiotherapy versus radiotherapy alone for brain metastases from breast cancer
2007-002531-83Phase 2Active
- Sponsor
- Institut Curie
- Start
- Aug 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in breast cancer and brain metastases (2 arms), sponsored by Institut Curie. Primary endpoint: Objective response rate at 6 weeks. Started Aug 2007; status: active.
02
Drugs
temozolomide
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on 2007-002531-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002531-83.